ISB Assistant Professor Dr. Sean Gibbons talked about the science behind statins in our most recent Research Roundtable virtual presentation. His talk was titled “Bugs vs. Drugs: How Our Unique Gut Microbiomes Shape Our Personalized Responses to Statins.”
New ISB research shows that different patient responses to statins can be explained by the variation in the human microbiome. The findings were published in the journal Med, and suggest that microbiome monitoring could be used to help optimize personalized statin treatments.
The strongest associations with weight loss success or failure – independent of BMI – are found in the genetic capacity of the gut microbiome. These new findings open the door to diagnostic tests that can identify people likely to lose weight with healthy lifestyle changes and those who might need more drastic interventions.
In ISB’s first-ever Research Roundtable event, Assistant Professor Dr. Sean Gibbons delivered a presentation titled “Gut-Check: Personalized Nutrition and Your Microbiome.” His talk covered a lot of ground, including recently published research showing how the health of our microbiomes can predict longevity, and how we can build and maintain a healthy gut microbiome.
The gut microbiome is an integral component of the body, but its importance in the human aging process is unclear. ISB researchers and their collaborators have identified distinct signatures in the gut microbiome that are associated with either healthy or unhealthy aging trajectories, which in turn predict survival in a population of older individuals.
ISB researchers and their collaborators are looking beyond the one-drug, one-solution approach that has thus far failed in Alzheimer’s disease research. Instead, they are focusing on other promising research avenues, such as the possible role of the gut microbiome in dementia.
ISB researchers examined the associations between the gut microbiomes of about 3,400 people and roughly 150 host characteristics. The team looked at diet, medication use, clinical blood markers, and other lifestyle and clinical factors, and found evidence that variations of the gut microbiome are associated with health and disease.
There is a dichotomy between Bacteroides- and Prevotella-dominated guts — two common gut bacterial genera — and there is a significant barrier when it comes to transitioning from one to the other.
A promising new open-source metabolic modeling tool provides microbiome researchers a path forward in predicting ecosystem function from community structure. News of the software package, called MICOM, was developed in part by researchers in ISB’s Gibbons Lab, and its uses were published in the journal mSystems.
Predicting the alpha diversity of an individual’s gut microbiome is possible by examining metabolites in the blood. The robust relationship between host metabolome and gut microbiome diversity opens the door for a fast, cheap and reliable blood test to identify individuals with low gut diversity.
The human microbiome is a relatively new area of research, and there are numerous questions surrounding it. What is the human microbiome? Can we change it? Does it make us sick? Keep us well? ISB Assistant Professor and microbiome researcher Dr. Sean Gibbons answers these questions — and many more.
“This new organ that we’re coming to recognize as the microbiome is part and parcel to the functionality of the whole system, and if it breaks down, if it starts to fall apart, we start to get sick,” said Dr. Sean Gibbons, ISB’s newest faculty member, in a WGBH Forum Network presentation.
Dr. Lee Hood was interviewed by Dr. Norman Swan, of the Australian Broadcasting Corporation, for the "Health Report" show. The interview aired on radio on Feb. 24, 2014. Listen to the radio segment. SEGMENT TRANSCRIPT: (Editor's note: ABC identifies Institute for Systems Biology as part of the University of Washington in the audio and in the transcript. ISB is an independent nonprofit organization and NOT a part of the UW.)…
